![Owen Philip Smith](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Owen Philip Smith
Directeur/Membre du Conseil chez Locki Therapeutics Ltd.
Postes actifs de Owen Philip Smith
Sociétés | Poste | Début | Fin |
---|---|---|---|
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Directeur/Membre du Conseil | 08/11/2019 | - |
Historique de carrière de Owen Philip Smith
Statistiques
Internationale
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Health Technology |
- Bourse
- Insiders
- Owen Philip Smith
- Expérience